Database analysis papers

Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Hollstein M, Moriya M, Grollman AP, Olivier M. Mutat Res. 2013 Jul-Sep;753(1):41-9..


Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Cancer 2012 Mar 1;118(5):1387-96.


TP53 mutations in human cancers: origins, consequences, and clinical use. Olivier M, Hollstein M, Hainaut P. Cold Spring Harb Perspect Biol 2010 Jan;2(1):a001008.


Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Hum Mutat. 2007 Jun;28(6):622-9.


TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. Oncogene. 2007 Apr 2;26(15):2157-65.


Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. Mathe, E, Olivier, M., Kato, S., Ishioka, C., Vaisman, II, Hainaut, P. Human Mutat 2006 27(2):163-72.


The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Kawaguchi T, Kato S, Otsuka K, Watanabe G, Kumabe T, Tominaga T, Yoshimoto T, Ishioka C. Oncogene. 2005 Oct 20;24(46):6976-81.


TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. IARC Sci Publ. 2004 (157):247-70.


Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. Cancer Res. 2003 Oct 15;63(20):6643-50.


Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9.


Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS,Hainaut P. Oncogene 2002 Oct 21;21(48):7435-51.


Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M,Hainaut P, Thornton JM. Hum Mutat 2002 Feb;19(2):149-64.


TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Hainaut P, Olivier M, Pfeifer GP. Mutagenesis 2001 Nov;16(6):551-3; author reply 555-6


TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Olivier M, Hainaut P. Semin Cancer Biol 2001 Oct;11(5):353-360.


p53 and human cancer: the first ten thousand mutations. Hainaut P., Hollstein M. Adv Cancer Res. 2000 77:81-137


Sources of bias in the detection and reporting of p53 mutations in human cancer: analysis of the IARC p53 mutation database. Hernandez-Boussard T, Montesano R, Hainaut P. Genet Anal. 1999 Feb;14(5-6):229-33


A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Hernandez-Boussard TM, Hainaut P. Environ Health Perspect. 1998 Jul;106(7):385-91. Erratum in: Environ Health Perspect 1998 Sep;106(9):A 421